The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Transmedics Group Inc (NASDAQ: TMDX) closed at $119.18 down -2.42% from its previous closing price of $122.14. In other words, the price has decreased by -$2.42 from its previous closing price. On the day, 0.6 million shares were traded. TMDX stock price reached its highest trading level at $123.01 during the session, while it also had its lowest trading level at $118.57.
Ratios:
For a deeper understanding of Transmedics Group Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 8.74 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.76. For the most recent quarter (mrq), Quick Ratio is recorded 7.13 and its Current Ratio is at 7.69. In the meantime, Its Debt-to-Equity ratio is 1.46 whereas as Long-Term Debt/Eq ratio is at 1.44.
On October 13, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $145.
On September 16, 2025, Evercore ISI started tracking the stock assigning a Outperform rating and target price of $155.Evercore ISI initiated its Outperform rating on September 16, 2025, with a $155 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Oct 29 ’25 when Basile Edward M sold 4,142 shares for $130.45 per share. The transaction valued at 540,324 led to the insider holds 2,866 shares of the business.
EDWARD BASILE bought 4,142 shares of TMDX for $540,324 on Oct 29 ’25. On Aug 06 ’25, another insider, Hassanein Waleed H, who serves as the President & CEO of the company, bought 8,400 shares for $118.68 each. As a result, the insider paid 996,912 and bolstered with 477,759 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMDX now has a Market Capitalization of 4072896000 and an Enterprise Value of 4126583552. As of this moment, Transmedics’s Price-to-Earnings (P/E) ratio for their current fiscal year is 48.14, and their Forward P/E ratio for the next fiscal year is 41.64. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.91. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.19 while its Price-to-Book (P/B) ratio in mrq is 11.46. Its current Enterprise Value per Revenue stands at 7.286 whereas that against EBITDA is 34.231.
Stock Price History:
The Beta on a monthly basis for TMDX is 2.06, which has changed by 0.38229966 over the last 52 weeks, in comparison to a change of 0.15085125 over the same period for the S&P500. Over the past 52 weeks, TMDX has reached a high of $145.50, while it has fallen to a 52-week low of $55.00. The 50-Day Moving Average of the stock is 0.68%, while the 200-Day Moving Average is calculated to be 13.14%.
Shares Statistics:
For the past three months, TMDX has traded an average of 962.42K shares per day and 1201070 over the past ten days. A total of 34.14M shares are outstanding, with a floating share count of 33.02M. Insiders hold about 3.36% of the company’s shares, while institutions hold 108.93% stake in the company. Shares short for TMDX as of 1761868800 were 7542390 with a Short Ratio of 7.84, compared to 1759190400 on 8143367. Therefore, it implies a Short% of Shares Outstanding of 7542390 and a Short% of Float of 37.849998.
Earnings Estimates
The market rating of Transmedics Group Inc (TMDX) is currently shaped by the ongoing analysis conducted by 7.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.76, with high estimates of $0.79 and low estimates of $0.71.
Analysts are recommending an EPS of between $2.82 and $2.38 for the fiscal current year, implying an average EPS of $2.59. EPS for the following year is $3.02, with 8.0 analysts recommending between $3.52 and $2.56.
Revenue Estimates
A total of 10 analysts believe the company’s revenue will be $156.34M this quarter.It ranges from a high estimate of $160.1M to a low estimate of $155M. As of. The current estimate, Transmedics Group Inc’s year-ago sales were $121.62MFor the next quarter, 10 analysts are estimating revenue of $170.61M. There is a high estimate of $181.5M for the next quarter, whereas the lowest estimate is $163.4M.
A total of 12 analysts have provided revenue estimates for TMDX’s current fiscal year. The highest revenue estimate was $604.8M, while the lowest revenue estimate was $599M, resulting in an average revenue estimate of $601M. In the same quarter a year ago, actual revenue was $441.54MBased on 12 analysts’ estimates, the company’s revenue will be $724.96M in the next fiscal year. The high estimate is $753.9M and the low estimate is $686.8M.
